Standard
Strategies to manage hepatitis C virus (HCV) disease burden. / Wedemeyer, H; Duberg, A S; Buti, M; Rosenberg, W M; Frankova, S; Esmat, G; Örmeci, N; Van Vlierberghe, H; Gschwantler, M; Akarca, U; Aleman, S; Balık, I; Berg, T; Bihl, F; Bilodeau, M; Blasco, A J; Brandão Mello, C E; Bruggmann, P; Calinas, F; Calleja, J L; Cheinquer, H; Christensen, P B; Clausen, M; Coelho, H S M; Cornberg, M; Cramp, M E; Dore, G J; Doss, W; El-Sayed, M H; Ergör, G; Estes, C; Falconer, K; Félix, J; Ferraz, M L G; Ferreira, P R; García-Samaniego, J; Gerstoft, J; Giria, J A; Gonçales, F L; Guimarães Pessôa, M; Hézode, C; Hindman, S J; Hofer, H; Husa, P; Idilman, R; Kåberg, M; Kaita, K D E; Kautz, A; Kaymakoglu, S; Krajden, M; Krarup, H; Laleman, W; Lavanchy, D; Lázaro, P; Marinho, R T; Marotta, P; Mauss, S; Mendes Correa, M C; Moreno, C; Müllhaupt, B; Myers, R P; Nemecek, V; Øvrehus, A L H; Parkes, J; Peltekian, K M; Ramji, A; Razavi, H; Reis, N; Roberts, S K; Roudot-Thoraval, F; Ryder, S D; Sarmento-Castro, R; Sarrazin, C; Semela, D; Sherman, M; Shiha, G E; Sperl, J; Stärkel, P; Stauber, R E; Thompson, A J; Urbanek, P; Van Damme, P; van Thiel, I; Vandijck, D; Vogel, W; Waked, I; Weis, N; Wiegand, J; Yosry, A; Zekry, A; Negro, F; Sievert, W; Gower, E.
In:
Journal of Viral Hepatitis, Vol. 21 , No. s1, 2014, p. 60-89.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Wedemeyer, H, Duberg, AS, Buti, M, Rosenberg, WM, Frankova, S, Esmat, G, Örmeci, N, Van Vlierberghe, H, Gschwantler, M, Akarca, U, Aleman, S, Balık, I, Berg, T, Bihl, F, Bilodeau, M, Blasco, AJ, Brandão Mello, CE, Bruggmann, P, Calinas, F, Calleja, JL, Cheinquer, H, Christensen, PB, Clausen, M, Coelho, HSM, Cornberg, M, Cramp, ME, Dore, GJ, Doss, W, El-Sayed, MH, Ergör, G, Estes, C, Falconer, K, Félix, J, Ferraz, MLG, Ferreira, PR, García-Samaniego, J
, Gerstoft, J, Giria, JA, Gonçales, FL, Guimarães Pessôa, M, Hézode, C, Hindman, SJ, Hofer, H, Husa, P, Idilman, R, Kåberg, M, Kaita, KDE, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, W, Lavanchy, D, Lázaro, P, Marinho, RT, Marotta, P, Mauss, S, Mendes Correa, MC, Moreno, C, Müllhaupt, B, Myers, RP, Nemecek, V, Øvrehus, ALH, Parkes, J, Peltekian, KM, Ramji, A, Razavi, H, Reis, N, Roberts, SK, Roudot-Thoraval, F, Ryder, SD, Sarmento-Castro, R, Sarrazin, C, Semela, D, Sherman, M, Shiha, GE, Sperl, J, Stärkel, P, Stauber, RE, Thompson, AJ, Urbanek, P, Van Damme, P, van Thiel, I, Vandijck, D, Vogel, W, Waked, I, Weis, N, Wiegand, J, Yosry, A, Zekry, A, Negro, F, Sievert, W & Gower, E 2014, '
Strategies to manage hepatitis C virus (HCV) disease burden',
Journal of Viral Hepatitis, vol. 21 , no. s1, pp. 60-89.
https://doi.org/10.1111/jvh.12249
APA
Wedemeyer, H., Duberg, A. S., Buti, M., Rosenberg, W. M., Frankova, S., Esmat, G., Örmeci, N., Van Vlierberghe, H., Gschwantler, M., Akarca, U., Aleman, S., Balık, I., Berg, T., Bihl, F., Bilodeau, M., Blasco, A. J., Brandão Mello, C. E., Bruggmann, P., Calinas, F., ... Gower, E. (2014).
Strategies to manage hepatitis C virus (HCV) disease burden.
Journal of Viral Hepatitis,
21 (s1), 60-89.
https://doi.org/10.1111/jvh.12249
Vancouver
Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G et al.
Strategies to manage hepatitis C virus (HCV) disease burden.
Journal of Viral Hepatitis. 2014;21 (s1):60-89.
https://doi.org/10.1111/jvh.12249
Author
Wedemeyer, H ; Duberg, A S ; Buti, M ; Rosenberg, W M ; Frankova, S ; Esmat, G ; Örmeci, N ; Van Vlierberghe, H ; Gschwantler, M ; Akarca, U ; Aleman, S ; Balık, I ; Berg, T ; Bihl, F ; Bilodeau, M ; Blasco, A J ; Brandão Mello, C E ; Bruggmann, P ; Calinas, F ; Calleja, J L ; Cheinquer, H ; Christensen, P B ; Clausen, M ; Coelho, H S M ; Cornberg, M ; Cramp, M E ; Dore, G J ; Doss, W ; El-Sayed, M H ; Ergör, G ; Estes, C ; Falconer, K ; Félix, J ; Ferraz, M L G ; Ferreira, P R ; García-Samaniego, J ; Gerstoft, J ; Giria, J A ; Gonçales, F L ; Guimarães Pessôa, M ; Hézode, C ; Hindman, S J ; Hofer, H ; Husa, P ; Idilman, R ; Kåberg, M ; Kaita, K D E ; Kautz, A ; Kaymakoglu, S ; Krajden, M ; Krarup, H ; Laleman, W ; Lavanchy, D ; Lázaro, P ; Marinho, R T ; Marotta, P ; Mauss, S ; Mendes Correa, M C ; Moreno, C ; Müllhaupt, B ; Myers, R P ; Nemecek, V ; Øvrehus, A L H ; Parkes, J ; Peltekian, K M ; Ramji, A ; Razavi, H ; Reis, N ; Roberts, S K ; Roudot-Thoraval, F ; Ryder, S D ; Sarmento-Castro, R ; Sarrazin, C ; Semela, D ; Sherman, M ; Shiha, G E ; Sperl, J ; Stärkel, P ; Stauber, R E ; Thompson, A J ; Urbanek, P ; Van Damme, P ; van Thiel, I ; Vandijck, D ; Vogel, W ; Waked, I ; Weis, N ; Wiegand, J ; Yosry, A ; Zekry, A ; Negro, F ; Sievert, W ; Gower, E. / Strategies to manage hepatitis C virus (HCV) disease burden. In: Journal of Viral Hepatitis. 2014 ; Vol. 21 , No. s1. pp. 60-89.
Bibtex
@article{3ba1ce1ea76d4c8ea82f1925a95242e1,
title = "Strategies to manage hepatitis C virus (HCV) disease burden",
abstract = "The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.",
keywords = "Adolescent, Adult, Aged, Aged, 80 and over, Antiviral Agents, Diagnostic Tests, Routine, Disease Eradication, Drug Therapy, Combination, Female, Global Health, Hepatitis C, Chronic, Humans, Incidence, Male, Middle Aged, Models, Statistical, Prevalence, Young Adult",
author = "H Wedemeyer and Duberg, {A S} and M Buti and Rosenberg, {W M} and S Frankova and G Esmat and N {\"O}rmeci and {Van Vlierberghe}, H and M Gschwantler and U Akarca and S Aleman and I Balık and T Berg and F Bihl and M Bilodeau and Blasco, {A J} and {Brand{\~a}o Mello}, {C E} and P Bruggmann and F Calinas and Calleja, {J L} and H Cheinquer and Christensen, {P B} and M Clausen and Coelho, {H S M} and M Cornberg and Cramp, {M E} and Dore, {G J} and W Doss and El-Sayed, {M H} and G Erg{\"o}r and C Estes and K Falconer and J F{\'e}lix and Ferraz, {M L G} and Ferreira, {P R} and J Garc{\'i}a-Samaniego and J Gerstoft and Giria, {J A} and Gon{\c c}ales, {F L} and {Guimar{\~a}es Pess{\^o}a}, M and C H{\'e}zode and Hindman, {S J} and H Hofer and P Husa and R Idilman and M K{\aa}berg and Kaita, {K D E} and A Kautz and S Kaymakoglu and M Krajden and H Krarup and W Laleman and D Lavanchy and P L{\'a}zaro and Marinho, {R T} and P Marotta and S Mauss and {Mendes Correa}, {M C} and C Moreno and B M{\"u}llhaupt and Myers, {R P} and V Nemecek and {\O}vrehus, {A L H} and J Parkes and Peltekian, {K M} and A Ramji and H Razavi and N Reis and Roberts, {S K} and F Roudot-Thoraval and Ryder, {S D} and R Sarmento-Castro and C Sarrazin and D Semela and M Sherman and Shiha, {G E} and J Sperl and P St{\"a}rkel and Stauber, {R E} and Thompson, {A J} and P Urbanek and {Van Damme}, P and {van Thiel}, I and D Vandijck and W Vogel and I Waked and N Weis and J Wiegand and A Yosry and A Zekry and F Negro and W Sievert and E Gower",
note = "{\textcopyright} 2014 John Wiley & Sons Ltd.",
year = "2014",
doi = "10.1111/jvh.12249",
language = "English",
volume = "21 ",
pages = "60--89",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley-Blackwell",
number = "s1",
}
RIS
TY - JOUR
T1 - Strategies to manage hepatitis C virus (HCV) disease burden
AU - Wedemeyer, H
AU - Duberg, A S
AU - Buti, M
AU - Rosenberg, W M
AU - Frankova, S
AU - Esmat, G
AU - Örmeci, N
AU - Van Vlierberghe, H
AU - Gschwantler, M
AU - Akarca, U
AU - Aleman, S
AU - Balık, I
AU - Berg, T
AU - Bihl, F
AU - Bilodeau, M
AU - Blasco, A J
AU - Brandão Mello, C E
AU - Bruggmann, P
AU - Calinas, F
AU - Calleja, J L
AU - Cheinquer, H
AU - Christensen, P B
AU - Clausen, M
AU - Coelho, H S M
AU - Cornberg, M
AU - Cramp, M E
AU - Dore, G J
AU - Doss, W
AU - El-Sayed, M H
AU - Ergör, G
AU - Estes, C
AU - Falconer, K
AU - Félix, J
AU - Ferraz, M L G
AU - Ferreira, P R
AU - García-Samaniego, J
AU - Gerstoft, J
AU - Giria, J A
AU - Gonçales, F L
AU - Guimarães Pessôa, M
AU - Hézode, C
AU - Hindman, S J
AU - Hofer, H
AU - Husa, P
AU - Idilman, R
AU - Kåberg, M
AU - Kaita, K D E
AU - Kautz, A
AU - Kaymakoglu, S
AU - Krajden, M
AU - Krarup, H
AU - Laleman, W
AU - Lavanchy, D
AU - Lázaro, P
AU - Marinho, R T
AU - Marotta, P
AU - Mauss, S
AU - Mendes Correa, M C
AU - Moreno, C
AU - Müllhaupt, B
AU - Myers, R P
AU - Nemecek, V
AU - Øvrehus, A L H
AU - Parkes, J
AU - Peltekian, K M
AU - Ramji, A
AU - Razavi, H
AU - Reis, N
AU - Roberts, S K
AU - Roudot-Thoraval, F
AU - Ryder, S D
AU - Sarmento-Castro, R
AU - Sarrazin, C
AU - Semela, D
AU - Sherman, M
AU - Shiha, G E
AU - Sperl, J
AU - Stärkel, P
AU - Stauber, R E
AU - Thompson, A J
AU - Urbanek, P
AU - Van Damme, P
AU - van Thiel, I
AU - Vandijck, D
AU - Vogel, W
AU - Waked, I
AU - Weis, N
AU - Wiegand, J
AU - Yosry, A
AU - Zekry, A
AU - Negro, F
AU - Sievert, W
AU - Gower, E
N1 - © 2014 John Wiley & Sons Ltd.
PY - 2014
Y1 - 2014
N2 - The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.
AB - The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.
KW - Adolescent
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Antiviral Agents
KW - Diagnostic Tests, Routine
KW - Disease Eradication
KW - Drug Therapy, Combination
KW - Female
KW - Global Health
KW - Hepatitis C, Chronic
KW - Humans
KW - Incidence
KW - Male
KW - Middle Aged
KW - Models, Statistical
KW - Prevalence
KW - Young Adult
U2 - 10.1111/jvh.12249
DO - 10.1111/jvh.12249
M3 - Journal article
C2 - 24713006
VL - 21
SP - 60
EP - 89
JO - Journal of Viral Hepatitis
JF - Journal of Viral Hepatitis
SN - 1352-0504
IS - s1
ER -